STE
Desconocido
GALAXY: GALAXY Gut and liver axis in alcoholic liver fibrosis
NOVO NORDISK INVEST 4 AS
participó en un
H2020:
H2020-PHC-2014-2015
Alcohol overuse is an important societal challenge with annual healthcare costs of over €22 billion in Europe. Alcohol is the main cause of...
2015-12-02 - 2021-12-31 | Financiado
2015-12-02 - 2021-12-31 | Financiado
EPoS: Elucidating Pathways of Steatohepatitis
NOVO NORDISK INVEST 4 AS
participó en un
H2020:
H2020-PHC-2014-2015
Strongly associated with the epidemics of obesity and type 2 diabetes mellitus (T2DM) that are testing healthcare systems worldwide, Non-Alc...
2015-04-07 - 2019-10-31 | Financiado
2015-04-07 - 2019-10-31 | Financiado
DEXLIFE: Mechanisms of prevention of type 2 diabetes by lifestyle intervention in subjects with pre diabetes...
NOVO NORDISK INVEST 4 AS
tramitó un
FP7:
Type 2 diabetes (T2DM) is preventable by sustained changes in diet and physical exercise. Despite this, modern societies are already approac...
Financiado
Financiado
BETABAT: Development of novel treatment strategies based on knowledge of cellular dysfunction in diabetes
NOVO NORDISK INVEST 4 AS
participó en un
FP7:
A reduction in functional pancreatic beta cell mass is the key feature of type 1 and type 2 diabetes. Beta cell failure is exacerbated in th...
Financiado
Financiado
METSY: Neuroimaging platform for characterisation of metabolic co morbidities in psychotic disorders
NOVO NORDISK INVEST 4 AS
participó en un
FP7:
The theme of this collaborative project is development and application of neuroimaging and bioinformatics tools to study lipid metabolism as...
Financiado
Financiado
SYSKID: Systems biology towards novel chronic kidney disease diagnosis and treatment
NOVO NORDISK INVEST 4 AS
participó en un
FP7:
Chronic kidney disease (CKD) affects up to 10% of the population. Besides eventual progression towards end stage renal disease CKD impacts t...
Financiado
Financiado
PRIORITY: Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabeti...
NOVO NORDISK INVEST 4 AS
participó en un
FP7:
Patients with diabetes are at risk of developing diabetic nephropathy, which will ultimately result in the requirement for renal replacement...
Financiado
Financiado
COSMOS: Developing an efficient e infrastructure standards and data flow for metabolomics and its interface...
NOVO NORDISK INVEST 4 AS
participó en un
FP7:
Metabolomics is an important phenotyping technique for molecular biology and medicine. It assesses the molecular state of an organism or col...
Financiado
Financiado
REDDSTAR: Repair of Diabetic Damage by Stromal Cell Administration
NOVO NORDISK INVEST 4 AS
participó en un
FP7:
50 million diabetic EU citizens are using approved anti-diabetic agents to control their glycaemia. However, suboptimal glycemic control lea...
Financiado
Financiado
* No se disponen de datos de la empresa actual.